Islet transplantation is a promising therapy for type 1 diabetes. However, chronic immunosuppression to control rejection of allogeneic islets induces morbidities and impairs islet function. T effector cells are responsible for islet allograft rejection and express Fas death receptors following activation, becoming sensitive to Fas-mediated apoptosis. Here, we report that localized immunomodulation using microgels presenting an apoptotic form of the 
T ype 1 diabetes is an autoimmune disease characterized by a loss of insulin-producing β -cell mass, and thereby glycaemic control, due to a coordinated immune response against β -cell specific antigens requiring CD4 + T cells [1] [2] [3] . Restoration of β -cell mass through allogeneic islet transplantation is currently the preferred clinical intervention to improve glycaemic control in patients with severe glycaemic instability [4] [5] [6] . However, the longevity of allogeneic grafts is limited not only by host immune responses, but also by secondary graft failure due to toxic effects of the chronic immunosuppression required to control rejection 7, 8 . Pathogenic T effector (T eff ) cells are the major culprit of islet allograft destruction 9, 10 . Therefore, a promising strategy to increase the functional longevity of islet allografts without the need for long-term immunosuppression comprises therapies that target T eff cells for elimination, mitigating their pathogenic function 11 . Upon activation, T cells upregulate Fas and become sensitive to FasL-mediated apoptosis-a process that plays a critical role in activation-induced cell death and tolerance to self-antigens 12 . Deficiency in Fas or FasL results in massive lymphoproliferation and autoimmune pathologies in rodents and humans, demonstrating a lack of compensatory mechanisms and the importance of this pathway for immune regulation 13 . Recognizing the immunomodulatory potential of this pathway, several groups have successfully used FasL gene therapy to mitigate allogeneic immune responses for graft acceptance in experimental animal models [14] [15] [16] [17] [18] . Although these interventions show efficacy, the unknown safety profile of sustained ectopic expression of FasL in target tissues, as well as technical and regulatory challenges of gene therapy, limit their clinical potential. Additionally, FasL only contributes to activationinduced cell death in its membrane-bound, oligomeric form 19 . Matrix metalloproteinases can cleave FasL into an extracellular soluble form that inhibits apoptosis and acts as a chemoattractant for neutrophils, accelerating the destruction of allografts 20 . To use FasL as an effective immunomodulatory agent, we previously reported the construction of a chimeric form of FasL with streptavidin (SA) (SA-FasL), in which the extracellular domain of FasL, lacking metalloproteinase sensitive sites, was cloned C-terminal to SA 21 . This protein exists as tetramers and oligomers with robust apoptotic activity on Fas-expressing cells. Pancreatic islets, chemically modified with biotin attached to the cell surface followed by engineering with SA-FasL, acquired an immune privileged status and survived indefinitely under the kidney capsule in the absence of chronic immunosuppression in an allogeneic transplant murine model 22 . However, this study was limited to islets that were chemically modified to present SA-FasL. Biomaterials engineered to present SA-FasL on their surface as off-the-shelf immunomodulatory products represent a significant advance over chemical modification of islets. This approach eliminates the need for islet chemical modification, which is associated with considerable technical and regulatory challenges, and establishes a translatable and potentially more effective immunomodulatory strategy with an improved safety profile for islets. Herein, we engineered a biomaterial for the sustained presentation of SA-FasL within the islet graft microenvironment.
Hydrogel particles for controlled SA-FasL presentation
Hydrogel microparticles (microgels) were synthesized from maleimide-terminated four-arm poly(ethylene) glycol (PEG-4MAL) macromers using microfluidics polymerization 23 . The PEG-4MAL platform enables stoichiometric, covalent incorporation of thiol-containing molecules, and provides improved crosslinking efficiency over other chemistries for the formation of structurally defined hydrogels 24 . PEG-4MAL exhibits minimal toxicity in vivo and is rapidly excreted in the urine 25 , which are important considerations for clinical applications. Biotinylated microgels were produced by reacting biotin-PEGthiol with PEG-4MAL macromers, and generating 150-μ m-diameter microgels crosslinked with dithiothreitol via microfluidics polymerization (Fig. 1a) . The resulting microgels displayed covalently tethered biotin capable of capturing SA with high affinity (Fig. 1b) . Moreover, the biotin-specific capture of SA on microgels varied linearly with the concentration of SA in the tethering solution, up to a saturating concentration of 150 μ g ml -1 (Fig. 1c) , demonstrating dose-dependent control of SA presentation on the microgel surface. As expected, the capture of SA-FasL on biotinylated microgels obeyed a similar dosedependent relationship (Supplementary Fig. 1 ). Importantly, the display of SA-FasL on microgels induced dose-dependent apoptosis in the A20 murine B-cell lymphoma cells (Fig. 1d) , which are sensitive to FasL-mediated apoptosis. In contrast with biotin-dependent tethering, direct covalent coupling of SA-FasL to the PEG-4MAL macromer eliminated SA-FasL apoptotic activity ( Supplementary Fig. 2 ), demonstrating the importance of biotin immobilization for the presentation of bioactive SA-FasL. These results show that SA-FasL tethered to biotinylated microgels retains potent apoptotic activity, and that the quantity of bioactive SA-FasL delivered can easily be controlled using this approach.
We cultured rat islets with SA-FasL-presenting microgels (an isletto-microgel ratio of 1:2) for 24 h to examine whether the functionalized material impacts islet health and function. No differences in metabolic activity ( Supplementary Fig. 3a) , glucose-stimulated insulin secretion ( Supplementary Fig. 3b ), secretion of pro-inflammatory cytokines ( Supplementary Fig. 3c ), live-dead staining ( Supplementary  Fig. 3d ), or insulin and glucagon expression patterns ( Supplementary  Fig. 3e ) were seen between islets co-cultured with SA-FasL-presenting microgels and control free islets. These data demonstrate that SA-FasLpresenting microgels do not negatively impact islet health or function.
Next, we investigated the retention of SA-FasL presented on microgels in vivo. SA-FasL, labelled with a near-infrared fluorescent dye, was immobilized on biotinylated microgels, which were implanted under the kidney capsule of mice. Longitudinal tracking of labelled SA-FasL was performed on an in vivo imaging system for 21 days. Images of the fluorescence signal show a concentrated signal localized to the area around the kidneys in mice receiving labelled SA-FasL-presenting microgels, whereas the fluorescence signal is diffuse for mice receiving labelled free SA-FasL without the microgel carrier (Fig. 2a) . In mice receiving only labelled SA-FasL, without the microgel delivery vehicle, the protein was rapidly cleared from the transplant site, with a 60% reduction in signal by day 1 post-implantation and negligible signal by day 7 after implantation ( Fig. 2b) . In contrast, mice receiving SA-FasL-presenting microgels displayed significantly higher levels of SA-FasL over time, with elevated levels comparable to the day 0 signal at the site of implantation over 11 days post-transplantation. Analysis of retention profiles using single exponential decay curve fits showed significantly longer retention times for SA-FasL-presenting microgels compared with free SA-FasL (half-life: 3.0 ± 0.8 days versus 0.70 ± 0.40 days; P < 0.0001). Furthermore, area-under-the-curve calculations demonstrated increased retention of SA-FasL for microgeltethered versus free protein (5.25 ± 0.87 versus 1.98 ± 0.14; P < 0.007).
We performed histology at sacrifice at day 21 and clearly observed microgels at the implant site ( Supplementary Fig. 4 ). This result supports the conclusion that the loss of fluorescence signal for the SA-FasL microgels arises from unbinding of SA-FasL from the biotinylated microgel and not degradation of the microgels. We expect that this biomaterial strategy for prolonged, local SA-FasL delivery in graft sites significantly enhances the local effects while minimizing risks of systemic effects of this potent immunomodulatory protein.
immunomodulatory properties of SA-FasL microgels
The immunomodulatory efficacy of microgels presenting SA-FasL was tested in an allogeneic islet transplantation setting. Unmodified allogeneic BALB/c islets were mixed with microgels, and the resulting mixture was transplanted under the kidney capsule of streptozotocin-diabetic C57BL/6 mice. Mice receiving unmodified islets and control biotinylated microgels acutely rejected all grafts (median survival time (MST) = 15 days; Fig. 3a) . Islets co-transplanted with SA-FasL-engineered microgels had significantly prolonged survival (MST = 31 days) with approximately 25% of the subjects surviving over 200 days before sacrifice (Fig. 3a) . Notably, > 90% (12/13) of grafts functioned and survived for the entire 200 day observation window in mice co-transplanted with unmodified islets and SA-FasL-presenting microgels when subjects were treated with a short course of rapamycin (0.2 mg kg -1 daily initiated on day 0 post-transplantation for 15 doses; Fig.  3a) . Immunostaining of the implant site of recipients with functioning grafts at 200 days revealed insulin-positive structures reminiscent of islets in close association with microgels, whereas no insulin-positive structures were observed in recipients with rejected grafts (Fig. 3b) . Intraperitoneal (i.p.) glucose tolerance tests demonstrated equivalent function of these long-term grafts compared with naïve mice (Fig. 3c) ; area-under-the-curve analyses showed no differences between naïve and long-term grafts (P = 0.20). In marked contrast, the same protocol with rapamycin injections but without SA-FasL-engineered microgels resulted in acute rejection (MST = 36 days) with similar performance to the SA-FasL-presenting microgel group (Fig.  3a) . Although the mechanistic synergy between SA-FasL and rapamycin in this model is presently unknown and may be complex, death receptor-mediated extrinsic apoptosis in T eff cells by SA-FasL 12 , and mitochondria-mediated intrinsic apoptosis by rapamycin 26 , are potential candidates. Representative blood glucose levels over time for graft recipients with SA-FasL-presenting microgels plus rapamycin or control microgels plus rapamycin are shown in Supplementary Fig. 5 . Nephrectomy in diabetic mice receiving islets and SA-FasL-presenting microgels plus rapamycin at day 100 post-transplantation rapidly restored hyperglycaemia ( Supplementary Fig. 6 ), demonstrating that diabetes reversal in these subjects was due to the graft. Increasing tenfold the surface density of SA-FasL on microgels had no significant improvement on graft survival ( Supplementary Fig. 7 ). We also compared the functional performance of SA-FasL-presenting microgels with SA-FasL-presenting islets as we previously showed that this strategy was effective in promoting graft acceptance 22 . We observed no differences in the effects of SA-FasL, with or without rapamycin administration, between SA-FasL presented on the surface of islets or microgels ( Supplementary Fig. 7 ). However, a major and significant advantage of microgel-based SA-FasL presentation is avoidance of the chemical modification of islets which may overcome a potential negative impact on islet viability and function and also provide a better translatable strategy as an off-the-shelf product. Furthermore, this result shows that SA-FasL does not have to be presented by the target tissue; that is, the islet graft, to overcome immune rejection. Taken together, these results show that simple co-transplantation of allogeneic islets and SA-FasLengineered microgels restores long-term glycaemic control without the use of chronic immunosuppression or islet chemical modification.
Because of the localized nature of immunomodulation, we assessed the systemic response of graft recipients to donor antigens in an in vitro proliferation assay (the gating strategy for flow cytometric analysis is depicted in Supplementary Fig. 8a ). Both CD4 + and CD8
+ T cells from long-term (> 200 days) islet graft recipients treated with SA-FasL-engineered microgels showed proliferative responses to donor as well as third-party antigens ( Fig. 4a and Supplementary Fig. 9 ). The observed responses were at similar magnitudes to those obtained using T cells from rejecting mice receiving unmodified microgels plus rapamycin. This result indicates that mice receiving SA-FasL-engineered microgels maintain systemic immune competence, and that the protection afforded by SA-FasL-engineered microgels remains localized to the graft, as reported previously in two transplant settings using FasL as an immunomodulatory molecule 15, 22 . To further elucidate the mechanism of graft acceptance, immune cell populations harvested from the spleen, graft-draining lymph nodes and graft were analysed using flow cytometry (the gating strategy for flow cytometric analysis is depicted in Supplementary  Fig. 8b ), with particular focus on T eff and T regulatory (T reg ) cells as targets of FasL-mediated immunomodulation ( Fig. 4b and Supplementary Fig. 10 ). We observed a general trend in decreased numbers of both CD4
+ and CD8 + T eff cells in the tissues of mice receiving SA-FasL-engineered microgels plus rapamycin compared with the control group receiving unmodified microgels alone or in combination with rapamycin ( Supplementary Fig. 11 ). Interestingly, the unmodified microgels plus rapamycin group showed a trend towards increased numbers of T reg cells that reached significance in the graft-infiltrating lymphocytes on day 7 post-transplantation. T reg cells have been shown to be less dependent on mammalian target of rapamycin signalling for proliferation and homoeostasis compared with T conventional cells 27 . Indeed, rapamycin has been used to selectively expand T reg cells both in vitro and in vivo 28, 29 . Under select conditions, rapamycin can positively impact the frequency and long-term survival of T eff cell memory precursors 30, 31 . However, the dose, treatment regimens, and presence and nature of antigens are important factors impacting the outcome of rapamycin treatment in relation to T reg versus T eff cells 31, 32 . Thus, the observed increases in the numbers of both T eff and T reg cells in the control group receiving rapamcyin are not surprising. We observed a trend towards an increased ratio of T reg to CD4
+ and CD8 + T eff cells in the graft SA-FasL-presenting or control microgels and unmodified BALB/c islets were co-transplanted under the kidney capsule of chemically diabetic C57BL/6 recipients. Rapamycin was used at 0.2 mg kg -1 daily i.p. injection for 15 doses starting the day of transplantation in the indicated groups. Animals were monitored for blood glucose levels, and two consecutive daily readings of ≥ 250 mg dl -1 was considered to indicate diabetes (rejection). Data comprise transplants performed from various islet isolations with the sample size indicating the number of treated mice. Survival curves were analysed by Mantel-Cox test (χ 2 = 59.98, d.f. = 3, P < 0.0001; two-tailed pair-wise comparisons with Bonferroni's correction, **P < 0.01, ***P < 0.001). b, Immunostaining of a long-term functioning graft (> 200 days) and a rejected graft from recipients receiving SA-FasL-presenting microgels showing insulin-positive structures (red) and DNA (blue). Scale bar: 100 µ m. Yellow arrowheads indicate microgels. Staining patterns are consistent for samples across different independent runs. c, Intraperitoneal glucose tolerance test on day 200 showing long-term islet grafts with function equivalent to naïve subjects. The sample size indicates the number of mice evaluated. The area-under-the-curve metric was computed using the trapezoid rule in GraphPad Prism and compared using the z-statistic (two-tailed P = 0.20).
(T reg :CD8
+ T eff ) and graft-draining lymph nodes (both T reg :T eff populations) in the groups receiving SA-FasL-engineered microgels plus rapamycin compared with the control groups receiving unmodified microgels alone or in combination with rapamycin (Fig. 4b) .
T reg cells are required for islet graft acceptance
T reg cells, similar to T eff cells, follow the inflammatory cues and infiltrate into rejecting grafts without a functional consequence 33, 34 . Because of the trend in the increased ratio of T reg to T eff cells, we conducted a depletion study to directly assess the role of T reg cells in the observed graft acceptance in our model. For these studies, BALB/c allogeneic islets were transplanted into transgenic C57BL/6 mice expressing the human diphtheria toxin (DT) receptor under the control of Foxp3. Unlike antibody-mediated partial T reg cell depletion, this FoxP3/DTR mouse model allows acute ablation of T reg cells and has been used extensively in transplantation and autoimmune settings to assess the role of T reg cells in controlling autoimmunity and graft rejection 35, 36 . In these FoxP3/ DTR mice, DT administration depletes T reg cells transiently for several days before returning to normal levels ( Supplementary Fig. 12a ). Importantly, DT administration has no effects on the blood glucose levels of FoxP3/DTR mice ( Supplementary Fig. 12b ). Chemically diabetic transgenic mice transplanted with allogeneic islets and SA-FasLengineered microgels under the transient cover of rapamycin established graft acceptance, as seen previously in C57BL/6 recipients, with mice maintaining graft function at day 50 post-transplantation (Fig. 5) . Depletion of T reg cells by administration of DT on day 50 resulted in rejection of all grafts by day 82 ( Fig. 5 ; MST = 72 days). In marked contrast, control mice without DT treatment maintained graft function for a 200 day experimental end-point. These results provide direct in vivo evidence for the dominant role of T reg cells in graft acceptance for mice receiving SA-FasL-presented microgels.
Application to a clinically relevant transplant site
The kidney capsule is an experimentally convenient transplant site for the study of cell delivery, but it has limitations for clinical adoption. We therefore examined allogeneic islet transplantation + and CD8 + T cells was assessed using antibodies to CD4 and CD8 molecules in flow cytometry and plotted as the percent division for each cell population (n = 3 mice per group for the microgel group; n = 5 mice per group for the microgel + rapa and SA-FasL microgel + rapa groups; mean ± s.e.; ANOVA with two-tailed pair-wise comparisons using Tukey's test). b, Analysis of T eff and T reg cells. Single cells prepared from the spleen (left), kidney-draining lymph nodes (middle) and kidney (right) of the indicated groups on days 3 and 7 post-islet transplantation were stained with fluorescence-labelled antibodies to cell surface molecules that define CD4 ) populations, and analysed using flow cytometry. The ratios of T reg to CD4 + T eff and CD8 + T eff are plotted (n = 2 mice per group for the microgel + rapa group; n = 3 mice per group for the microgel and SA-FasL microgel + rapa groups; mean ± s.e.; ANOVA with two-tailed pair-wise comparisons with Bonferroni's correction).
into the murine epididymal fat pad. The epididymal fat pad in mice is analogous to the omentum in humans. Importantly, the omentum represents a clinically relevant islet transplant site 37, 38 .
To retain islets in this site, grafts were delivered within a proteasedegradable PEG hydrogel with controlled vascular endothelial growth factor release that improves islet engraftment 39 . In agreement with our results for the kidney capsule site, allogeneic islets co-transplanted with SA-FasL microgels under a brief cover-ofrapamycin treatment showed significantly improved survival in diabetic mice compared with controls (P < 0.0008; Fig. 6a ). The islet grafts in this model also normalized blood glucose levels, demonstrating function (Supplementary Fig. 13 ). It is important to note that the transplant protocol (that is, the SA-FasL dose and rapamycin delivery route/regimen) has not been optimized for the epididymal fat pad, and we expect that optimization of these parameters will further improve graft performance in this site. Immunostaining of the transplant site in mice with functioning islet grafts in the SA-FasL-presenting microgels plus rapamycin group revealed many structures that stained positive for insulin and glucagon (Fig. 6b and isotype controls in Supplementary  Fig. 14) , whereas no such insulin-and glucagon-positive structures were found in mice receiving islets with control microgels. Finally, as an initial assessment of the potential toxicity of the SA-FasL microgel treatment, we measured serum levels of liver enzymes and performed histology for the liver and kidney in long-term recipients (> 60 days) (Fig. 6c) . Liver enzyme levels were within the normal range and there were no differences between SA-FasL-presenting microgels and controls. Similarly, there were no differences in gross liver or kidney tissue structure. Taken together, these results demonstrate that the SA-FasL microgel strategy improves transplanted islet function without chronic immunosuppression in a clinically relevant transplant site with an acceptable safety profile. 
Outlook
The results presented in this study are consistent with the established role of FasL in physiological immune privilege for selected tissues, such as the anterior chamber of the eye and the testes [40] [41] [42] . The observed protection against rejection required T reg cells and was localized to the graft, as long-term recipients generated a normal systemic response to the donor antigens, implying immune privilege. This is consistent with a study demonstrating that primary myoblasts transfected to express FasL conferred immune privilege to co-transplanted allogeneic islets 15 . Furthermore, we previously demonstrated that allogeneic islets chemically modified to display SA-FasL protein on their surface under short cover of rapamycin overcame rejection by inducing graft-localized tolerance and immune privilege, maintained by T reg cells 22 . Engineering microgels with SA-FasL allows controlled loading, presentation and retention of SA-FasL protein within the graft microenvironment for immunomodulation. This is a unique advantage over gene therapy because uncontrolled, continuous expression of FasL, which possesses pleiotropic functions and different modes of expression that may be differentially regulated by the target tissues (membrane bound or soluble), may have unintended consequences. Indeed, ectopic expression of FasL using gene therapy for immunomodulation in transplantation settings has resulted in mixed and opposing outcomes, with some studies showing a detrimental impact of FasL expression on graft survival 43 . The localized and sustained presentation of SA-FasL with robust apoptotic function using microgels overcomes complications associated with ectopic expression of wild-type FasL in target tissues using gene therapy. This localized immunomodulation concept also limits potential toxicities associated with agonistic antibodies against Fas for immunomodulation 44 . Lastly, SA-FasL-engineered microgels provide the flexibility of an off-the-shelf product for wider clinical applications, as these immunomodulatory materials can be prepared at the time of transplantation and simply co-mixed with islets for delivery without the need of encapsulating islets or chemically modifying islets to present proteins. Importantly, we demonstrate that co-transplantation of SA-FasL microgels and allogeneic islets in the epididymal fat pad-a clinically relevant transplant site analogous to the omentum in humans-results in graft tolerance and function without chronic immunosuppression. Additional studies in large animal or humanized mouse models will be necessary for further proof of efficacy and translation to the clinic.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41563-018-0099-0. 

Microgel synthesis and characterization.
A microgel precursor solution containing 5% w/v PEG-4MAL (20 kDa; Laysan Bio) and 1.0 mM biotin-PEGthiol (1 kDa; Nanocs) was reacted for 15 min in phosphate buffered saline (PBS). This precursor was dispersed into droplets and subsequently crosslinked within mineral oil (Sigma) containing 2% SPAN80 (Sigma) and a 1:15 emulsion of 30 mg ml -1 dithiothreitol (Sigma) on a microfluidic chip, as described previously 23 . Control microgels that did not contain biotin-PEG-thiol were also synthesized. After washing microgels 5 times by centrifugation in 1% bovine serum albumin (Sigma) in PBS, 10 4 microgels were incubated with varying concentrations of a streptavidin-Alexa Fluor 488 conjugate for 30 min in 500 μ l PBS, and were washed 5 times by centrifugation to remove unbound SA. Microgels from each sample were placed in a 96-well plate and fluorescence was measured on a plate reader (Perkin Elmer HTS 7000). Biotin and control microgels were also synthesized with a covalently bound peptide (GRGDSPC)-Alexa Fluor 594 conjugate for microgel visualization, and were fluorescently imaged to confirm biotin-specific SA immobilization.
In vitro SA-FasL bioactivity. Some 10 4 microgels, with or without biotin, were co-incubated for 30 min in 500 μ l PBS with 1% bovine serum albumin containing varying concentrations of SA-FasL. Microgels were washed 8 times by centrifugation to remove unbound SA-FasL, and incubated with 10 6 A20 cells (ATCC) in 1.0 ml media. After 18 h, the cells were stained with markers of early and late apoptosis (APC annexin V and propidium iodide, BD Biosciences). Samples were analysed by flow cytometry (Accuri C6 flow cytometer), and cells staining positive for either marker were considered apoptotic. Three independent runs of this experiment were performed, with consistent results.
In vitro cytocompatibility of SA-FasL conjugated microgels. All animal procedures were performed under protocols approved by the Georgia Institute of Technology Institutional Animal Care and Use Committee (IACUC) and in accordance with National Institutes of Health (NIH) guidelines. Rat pancreatic islets were isolated from Lewis male donors (250-300 g; Charles River) and cultured overnight. Five hundred (500) islet equivalents (IEQ) in 300 μ l of complete Connaught Medical Research Laboratories medium was co-cultured with 1,000 SA-FasL conjugated microgels for an additional 24 h. Islets were then analysed for metabolic activity via MTT (Promega); live/dead samples were visualized using the Viability/Cytotoxicity Kit (Invitrogen) and a Zeiss LSM 710 inverted confocal microscope. A static glucose-stimulated insulin-release assay was used to assess the insulin secretion of islets post co-culture, stimulating with low (3 mM) and high Krebs buffer (11 mM) for 1 h each. A second exposure to basal conditions was performed for an additional hour. A rat insulin enzyme-linked immunosorbent assay (Mercodia) was used to quantify glucose-stimulated insulin-release samples. Inflammatory cytokines from co-culture supernatant were analysed via a multiplexing magnetic bead-based antibody detection kit (MILLIPLEX Rat Cytokine Panel with interferon-γ -, interleukin (IL)-1b, IL-6, IL-17A, monocyte chemoattractant protein 1 (MCP-1) and macrophage inflammatory protein 1a (MIP-1a)) following the manufacturer's instructions. Some 50 μ l of supernatant from three independent wells was analysed using a MAGPIX system with Analyst analysis software (MILLIPLEX 5.1; Merck). Standard curves for each analyte were generated using standards provided by the manufacturer. Immunostaining analysis of insulin and glucagon was performed post co-culture by fixing islet samples in 10% formalin for 1 h. Whole samples were stained in suspension for insulin (Dako A0564, 1:100), glucagon (Abcam ab10988, 1:50) and 4',6-diamidino-2-phenylindole (Invitrogen, 1:500). Whole mount samples were imaged for insulin (yellow), glucagon (magenta) and 4',6-diamidino-2-phenylindole (blue). In vitro cytocompatibility data were collected from 2 independent islet isolation experiments, with representative data presented as the mean ± s.d. of group replicates (n = 3 biological independent samples for each group).
In vivo SA-FasL tracking. SA-FasL was labelled with Alexa Fluor 750 NHS Ester (Thermo Fisher Scientific), and free dye was removed by desalting in a Zeba column (7K MWCO; Thermo Fisher Scientific) three times. Some 3.0 μ g of labelled SA-FasL was immobilized onto 2,000 biotin microgels by incubation for 30 min followed by 5 wash steps. Microgels presenting SA-FasL or free SA-FasL were implanted under the kidney capsule of C57Bl/6 recipients (n = 8 mice per group), and the signal intensity and distribution were monitored longitudinally using an IVIS SpectrumCT imaging system (PerkinElmer). Intensity measurements were normalized to day 0 values. Nonlinear single exponential decay curve fits were performed in GraphPad Prism and the retention time was compared using a t-test. The area-under-the-curve metric was calculated for each group, and a Welch's ttest was used to compare groups.
Islet transplantation. All animal procedures were performed under protocols approved by the University of Louisville and Georgia Institute of Technology IACUC, and in accordance with NIH guidelines. BALB/c pancreatic islets were isolated using Liberase TL (Roche Life Science) as a digestive enzyme, and purified by a Ficoll density gradient as previously published 21 . To biotinylate islets, overnight cultured islets were incubated in 5 μ M EZ-Link Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific) for 30 min at room temperature, and washed extensively with PBS to remove unbound biotin solution. Biotinylated islets and microgels were engineered with SA-FasL (~150 ng per 500 islets and 1-10 µ g per 1,000 microgels). For kidney capsule experiments, 500 islets were co-transplanted with 1,000 microgels into streptozotocin-diabetic (200 mg kg -1 i.p.; diabetes (> 250 mg dl -1 ) confirmed on two consecutive days), C57BL/6 or B6.129(Cg)-Foxp3 tm3(DTR/GFP)Ayr /J (C57BL/6-FoxP3 EGFP/DTR ) recipients, where indicated. For T reg depletion, islet graft recipients were injected i.p. with DT (50 µ g kg -1 body weight), and depletion was confirmed in peripheral blood lymphocytes using flow cytometry. Selected groups were also treated i.p. with rapamycin at 0.2 mg kg -1 daily for 15 doses starting the day of transplantation. Unmodified BALB/c islets co-transplanted with unmodified microgels were used as controls. For epididymal fat pad transplantation, a 2 cm incision was made in the lower abdomen and the epididymal fat pads were exposed. Microgels (1,200 microgels conjugated with SA-FasL) and 600 IEQ were placed in each fat pad, which was then sealed with an in situ crosslinked PEG hydrogel containing vascular endothelial growth factor 39 . The incision was sutured, and the skin closed using surgical staples. The blood glucose and body weight of recipients were monitored every morning. Blood glucose levels ≥ 250 mg dl -1 for two consecutive daily measurements were considered rejected. An intraperitoneal glucose tolerance test was performed on day 200 post-transplantation after 6 h fasting using 2 g kg -1 glucose solution (25%). Blood glucose levels were assessed by tail prick before injection, and 10, 20, 30, 60, 90 and 120 min after injection. Data were graphed using GraphPad Prism, and the Mantel-Cox test was used to determine the significance between groups. P < 0.05 was considered significant. For some epididymal fat pad transplants (two mice per group), blood samples were collected at 50-70 days post-transplantation. Anaesthesia was induced by administering xylazine and ketamine, after which animals were bled via a cardiac puncture. Blinded blood samples were deposited in serum separator tubes and sent to ANTECH Diagnostics for analysis. Full necropsies were also performed for evidence of any gross abnormalities posttransplantation. Explanted kidneys and livers were preserved in 10% formalin solution and processed and stained with haematoxylin and eosin. Microscopy was performed using an optical microscope (Zeiss 510), and the images were taken using AxioVision software. The images presented are representative of all samples collected (n = 8 mice per group).
Immune monitoring. Spleen, kidney and kidney-draining lymph nodes were harvested from rejecting and long-term mice (> 200 days). Single cells were prepared from the spleen and lymph nodes by gentle mechanical dispersion, and from islet-harbouring kidneys by collagenase digestion. Cells were stained using antibodies to cell surface markers (Alexa Fluor 700-CD4 Ab, 1:200 (BD Biosciences 557956); APC-Cy7-CD8 Ab, 1:100 (BD Biosciences 557654); PECy7-CD25 Ab, 1:100 (eBiosciences, 25-0251-82), eFluor 450-CD44 Ab, 1:100 (eBiosicence 48-0441-82) and PerCP-Cy5.5-CD62L Ab, 1:200 (eBioscience 45-0621-82)). Intracellular FoxP3 staining was carried out on fixed/permeablized cells using a FoxP3 Transcription Factor Staining Buffer set (diluted 1:20; eBioscience 11-5773-82). Data were collected using BD LSR II and analysed using Diva software and FlowJo 9.8. Data were graphed using GraphPad Prism, and t-tests with Welch's correction were used to determine the significance between groups. P < 0.05 was considered significant. Proliferation assay. Splenocytes harvested from a selected group of transplant recipients from different isolations were labelled with carboxyfluorescein succinimidyl ester (CFSE) and used as responders to irradiated (2,000 cGy) splenocytes from donor or third-party C3H mice in a standard in vitro proliferation assay 21 . The groups tested were microgel plus rapa (n = 3), SA-FasL microgel (n = 5) and SA-FasL microgel plus rapa (n = 5). After 4 days in culture, cells were stained with 7AAD and fluorescence-conjugated antibodies against CD4 (1:200; BD Biosciences 557956) and CD8 (1:100; BD Biosciences 557654), and analysed for CFSE dilution by gating on live cells using BD LSR II. Data were analysed using Diva software and graphed using GraphPad Prism, and Welch's t-test was used to determine the significance between groups. P < 0.05 was considered significant.
Confocal microscopy.
After the observation period of 200 days, long-term isletbearing kidneys were snap frozen in O.C.T. Compound (Sakura Tissue-Tek) by submerging them in methyl butane (Sigma) on dry ice. Tissues were cut in 10-µ mthick slices using a Bright OTF5000 cryomicrotome (Rose Scientific) and put on frosted slides for staining. Slides were fixed in 4% paraformaldehyde, incubated in 0.5% Triton X-100, and blocked in 0.1% bovine serum albumin, 5% goat serum and rat anti-mouse CD16/CD32 (BD Pharmingen). Staining was performed using rabbit anti-glucagon monoclonal antibody (8233S, 1:100; Cell Signaling Technology) and guinea pig anti-insulin polyclonal antibody (A0564, 1:100; Dako) as primary antibodies, followed by washing and staining with Alexa Fluor 647-conjuaged goat anti-rabbit antibody (A21244, 1:100; Life Technologies) and Alexa Fluor 555-conjugated anti-guinea pig antibody (A21435, 1:300; Invitrogen). Hoechst 33342 (H3570, 1:25; Molecular Probes) was used to stain the DNA. Fluorescence images were obtained using a Leica TCS SP5 confocal microscope under 10× magnification.
Statistical analyses. Statistical analyses were applied to biologically independent samples (separate wells of samples, plates of cells or mice) from every single experiment. Experiments were repeated at least twice, and the numbers of repeats are indicated in the figure legends. For all ex vivo islet studies, at least three biological replicates were used across two different islet isolations. For in vivo data, groups comprise transplants across multiple islet isolations, and the sample size was determined based on power calculations to detect 20% differences among the means using variances from previous or pilot experiments. Animals were randomized among control and treatment groups, keeping the initial average weight and blood glucose levels similar for all groups. All animals were used for analysis unless they died or had to be euthanized because of pre-defined euthanasia criteria (significant weight loss or unresponsive to external stimuli) according to IACUC-approved protocols. Treated diabetic animals that did not achieve primary function (defined as five consecutive blood glucose readings < 250 mg dl -1 ) were excluded from the analysis, as this is an effect related to poor isolation outcomes and tissue quality, rather than the experimental groups being evaluated. Blood glucose measurements were performed by blinded and non-blinded personnel in a random fashion. Animals were checked in a rotation schedule by four different users. All blood glucose measurements were electronically and time-stamp recorded. The sample sizes for each experimental group and the statistical test used to determine significant differences among groups are reported in the appropriate figure legends. GraphPad Prism 7 was used for data analysis and representation, and P < 0.05 was considered statistically significant. Non-parametric tests were used if the data did not meet the assumptions of analysis of variance (ANOVA), and two-tailed pair-wise comparisons using Bonferroni or Tukey's tests were used. For t-tests, Welch's correction was used if the s.d. for the two groups was not equivalent. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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The data that support the plots within this paper are available from the corresponding authors upon request.
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For isolations for allogeneic transplants in EFP: Balb/C females were used as donors (age between 7-9 weeks). Recipients of allo tranplants in EFP are B6 male mice from 8-9 weeks in age. For in vitro compatibility islets were isolated from male Lewis Rat from 250-300 g (9-11 weeks). For kidney capsule transplants, male and female Balb/c were used for isolations between (5-9 weeks).
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Methodology Sample preparation
Spleen, kidney draining lymph nodes and graft bearing kidney were harvested. Spleen and Kidney draining lymph nodes were processed using frosted slides ends. Single cells from spleen were treated with RBC lysis buffer. For graft infiltrating lymphocytes, kidney capsule was torn apart using forceps in sterile PBS to release islet mass. Islet mass along with kidney capsule were then processed using frosted slides and enzymatic digestion were performed when needed. Cells were counted then processed for flow cytometry analysis. Cell population abundance NA
Gating strategy
For immunophenotyping, cell populations were gated based on forward and side scatter followed by doublet exclusion . The single cells were subjected to CD4 and CD8 gating. CD4 and CD8 positive cells were then subjected to CD44 vs CD62L gating. CD44hi CD62Llo were defined as effector T cells, CD44hi CD62Lhi were defined as central memory T cells where as CD44lo CD62Lhi as naive T cells. CD4 positive cells were further subjected to FoxP3 vs CD25. Isotype control was used against CD25 and FoxP3 to separate positive and negative populations. For immune cells proliferation assay, live cells were gated as 7AAD negative population followed by SSC-A vs FSC-A gating. The resulting population was then subjected to CD4 vs CD8 gating. Each CD4 or CD8 positive population were then subjected to FSC-A vs CFSE gating.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
